Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma
Open Access
- 28 February 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 29 (10) , 1979-1985
- https://doi.org/10.1093/carcin/bgn041
Abstract
Pulmonary adenocarcinoma (PAC) is the leading type of lung cancer in smokers and non-smokers that arises in most cases from small airway epithelial cells. PAC has a high mortality due to its aggressive behavior and resistance to cancer therapeutics. We have shown previously that the proliferation of human PAC cells NCI-H322 and immortalized human small airway epithelial cells HPL1D is stimulated by cyclic adenosine monophosphate (cAMP)/protein kinase A-dependent phosphorylation of cyclic adenosine monophosphate response element-binding (CREB) protein and transactivation of the epidermal growth factor receptor and that this pathway is activated by beta-1-adrenoreceptors (β 1 -ARs) and the non-genomic estrogen receptor beta. Our current in vitro studies with HPL1D and NCI-H322 cells showed that signaling via the gamma-amino butyric acid receptor (GABA B R) strongly inhibited base level and isoproterenol-induced cAMP, p-CREB, cyclic adenosine monophosphate response element-luciferase activity and p-extracellular regulated kinase-1 (ERK1)/2 and effectively blocked DNA synthesis and cell migration. The inhibitory effects of gamma-amino butyric acid (GABA) were disinhibited by the GABA B R antagonist CGP-35348 or GABA B R knockdown. Immunohistochemical investigation of hamster lungs showed significant underexpression of GABA in animals with small airway-derived PACs induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). These findings suggest that GABA may have tumor suppressor function in small airway epithelia and the PACs derived from them and that downregulation of GABA by NNK may contribute to the development of this cancer in smokers. Our findings suggest that marker-guided treatment with GABA or a GABA B R agonist of individuals with downregulated pulmonary GABA may provide a novel targeted approach for the prevention of PAC in smokers.Keywords
This publication has 36 references indexed in Scilit:
- GABAB receptor is a novel drug target for pancreatic cancerCancer, 2008
- Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugsInternational Journal of Cancer, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- The ErbB/HER receptor protein-tyrosine kinases and cancerBiochemical and Biophysical Research Communications, 2004
- Effects of Germinated Brown Rice Extracts with Enhanced Levels of GABA on Cancer Cell Proliferation and ApoptosisJournal of Medicinal Food, 2004
- Classification of Proliferative Pulmonary Lesions of the MouseCancer Research, 2004
- Effects of Neurotransmitters on the Chemokinesis and Chemotaxis of MDA-MB-468 Human Breast Carcinoma CellsBreast Cancer Research and Treatment, 2003
- The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells.2002
- Diversity of gene expression in adenocarcinoma of the lungProceedings of the National Academy of Sciences, 2001
- Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamstersZeitschrift für Krebsforschung und Klinische Onkologie, 2000